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Aberrant DNA hypermethylation favors tumor escape
from host’s immune recognition by decreasing the
expression of tumor-associated antigens (TAA) (e.g.,
cancer testis antigens (CTA)), HLA, co-stimulatory
molecules that are all required for efficient immune
recognition of cancer cells. Thus, increased levels of
DNA methylation in cancer cells might contribute
to reduced clinical efficacy of immunotherapeutic
approaches. SGI-110 is a dinucleotide of decitabine
(DAC) and deoxyguanosine formulated as a low
volume SQ injection which in the clinic, provides more
extended DAC exposure compared to DAC IV. The
observed superior PK profile offers the potential of
improved biological and clinical activity with a better
safety profile compared to currently available hypo-
methylating agents. We recently demonstrated that SGI-
110 induced/up-regulated CTA expression in cancer
cells of different histotype at both mRNA and protein
levels. Quantitative methylation-specific PCR analyses
identified hypomethylation of MAGE-A1 and NY-ESO-1
promoters in SGI-110-treated cancer cells, demonstrat-
ing a direct role of pharmacologic DNA demethylation
in CTA expression. SGI-110 also up-regulated the
expression of HLA class I and ICAM-1, resulting in an
improved recognition of cancer cells by TAA-specific
CTL. These immunomodulatory properties of SGI-110
are further supported by in vivo findings with human
melanoma xenografts. Furthermore, preliminary data,
generated in a syngeneic model of murine cancer,
demonstrate the synergistic anti-tumor effectiveness of
SGI-110 when administered in combination with
immunostimulatory antibodies (i.e., anti-CTLA-4
and -PD-1). These findings were extended to the clinical
setting, where the hypomethylating activity of SGI-110
on CTA-specific promoters and the resulting induction/
up-regulation of NY-ESO-1, MAGE-A1, MAGE-A3
expression were characterized in PBMC from MDS or
AML patients. Together, these preclinical and clinical
data suggest that SGI-110 in addition to having direct
anti-tumor activity as a single agent may sensitize tumor
cells to agents acting through the immune system and
hence it may increase their clinical activity. These evi-
dences, together with the favorable pharmacologic and
pharmacokinetic features of SGI-110, provide a strong
scientific rationale to develop new anti-cancer therapies
based on the combined efficacy of SGI-110 and immu-
notherapeutic strategies.
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